Investing Profile

Jim Tananbaum

VCInvestorCEOFounder
Founder and CEO at Foresite Capital.
foresitecapital.com/people/ji...San Francisco, California
Photo of Jim Tananbaum, Investor at Foresite Capital

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
Harvard Business School Network
508 CONNECTIONS
Massachusetts Institute of Technology Network
250 CONNECTIONS
Yale University Network
182 CONNECTIONS
Harvard Medical School Network
28 CONNECTIONS
Sierra Ventures Network
16 CONNECTIONS
cb
$100K - $5.0M
$1.5M
35
$668M
CompanyStageDateRound SizeTotal Raised
Foresight Diagnostics
Series BJul 2024$33M
Series BApr 2023$59M
$110M
Co-investors: Shahram Seyedin-Noor (Civilization Ventures), Vikram Bajaj (Foresite Capital)
Element Biosciences
Series DJul 2024$280M
Series CJun 2021$280M
$550M
Co-investors: Bryan Roberts (Venrock)
Alumis
Series CMar 2024$260M
Series AMay 2021$70M
$330M
Co-investors: Richard Gaster (venBio), Vikram Bajaj (Foresite Capital), Michael Rome (Foresite Capital)
Genomics
Series CJan 2024$45M
Series UnknownMar 2021$30M
$84M
Co-investors: Stephen Knight (F-Prime Capital Partners)
evonetix
Series BFeb 2023$24M
Series BMar 2020$30M
$66M
Co-investors: Armen Vidian (Recode Ventures), Ameena El-Bibany (Artis Ventures (AV)), Vishal Gulati (Molten Ventures)
DNAnexus
Series HMar 2022$200M
Series GJun 2020$100M
Series FFeb 2019$68M
Series EJan 2018$58M
$460M
Co-investors: Manu Kumar (K9 Ventures), Jeff Clavier (Uncork Capital), Krishna Yeshwant (GV (Google Ventures)), Rob Hayes (First Round Capital), Michael Rubin (Northpond Ventures), Michael G. Rubin, Nat Goldhaber
ImmPACT Bio
Series BJan 2022$140M
$140M
Co-investors: Cindy Xiong (Foresite Capital), Yvonne Yamanaka (venBio), Richard Gaster (venBio)
XinThera
Series BAug 2021$50M
$50M
Co-investors: Carl Gordon (OrbiMed Advisors), Michael Rome (Foresite Capital)
Founder and CEO Foresite Capital ManagementPresent
Co-Founder and Managing Director PVP2 & PVP3 Prospect Venture PartnersPresent
Co-Founder and Chief Executive Officer Theravance (THRX)Present
Partner Sierra Ventures1993 - 1997
Co-Founder and CEO GelTex (acquired by Genzyme for $1.6 B)1991 - 1992
Harvard Business School mba
Harvard Medical School Doctor of Medicine (MD)
Massachusetts Institute of Technology Master of Science (M.S.) HST - information theory
Yale University BS BSEE, Math, computer science